Capros (Phyllanthus emblica extract)

Capros is a patented, water-soluble extract of Phyllanthus emblica (Indian gooseberry) standardized to low-molecular-weight hydrolyzable tannins, including emblicanin A, emblicanin B, pedunculagin, and punigluconin. These polyphenols exert cardiovascular benefits primarily by inhibiting lipid peroxidation, scavenging free radicals, and modulating endothelial nitric oxide bioavailability.

Origin & History

Capros is a branded standardized aqueous extract derived from the fruits of Phyllanthus emblica L. (Indian gooseberry or amla), a tree native to India and Southeast Asia. The extract is produced via hot water extraction assisted by ultrasonication, yielding a product rich in polyphenols and hydrolyzable tannins.

Historical & Cultural Context

Phyllanthus emblica (amla) has been used for over 3,000 years in Ayurveda, the traditional Indian medicine system, primarily for digestive health, rejuvenation (rasayana), cardiovascular support, and diabetes management. It has been traditionally valued as an antioxidant tonic to promote longevity and vitality.

Health Benefits

• Improves cardiovascular health by reducing LDL cholesterol by 21.8% and increasing HDL by 22.16% in metabolic syndrome patients (Strong evidence, PMID: 31060549)
• Enhances endothelial function with reflection index reduction >6% in 12-week clinical trial (Strong evidence, PMID: 31060549)
• Reduces oxidative stress by increasing nitric oxide and glutathione while decreasing malondialdehyde levels (Strong evidence, PMID: 31060549)
• Lowers inflammation markers including hsCRP in overweight/obese adults (Moderate evidence, PMID: 25756303)
• Supports healthy blood pressure and multiple CVD risk factors in 12-week trials (Moderate evidence, PMID: 25756303)

How It Works

Capros's hydrolyzable tannins—emblicanin A and B—inhibit NADPH oxidase-driven superoxide production and suppress NF-κB signaling, reducing vascular inflammation and endothelial dysfunction. The polyphenols upregulate endothelial nitric oxide synthase (eNOS) activity, improving nitric oxide bioavailability and promoting vasodilation. Additionally, Capros inhibits HMG-CoA reductase activity and reduces oxidized LDL, contributing to its lipid-lowering and anti-atherosclerotic profile.

Scientific Research

Two randomized, double-blind, placebo-controlled trials have tested Capros: one with 59 metabolic syndrome patients showing significant improvements in endothelial function, lipids, and oxidative stress at 500-1000mg daily (PMID: 31060549), and another with 120 overweight/obese adults demonstrating reduced cardiovascular risk factors at 500mg daily (PMID: 25756303). Both 12-week studies showed good tolerability with no adverse effects on liver or kidney function.

Clinical Summary

A 12-week randomized, double-blind, placebo-controlled trial (PMID: 31060549) in metabolic syndrome patients demonstrated that 500 mg/day of Capros reduced LDL cholesterol by 21.8%, increased HDL by 22.16%, and improved endothelial function as measured by a reflection index reduction greater than 6%. The same trial observed meaningful reductions in total cholesterol and triglycerides alongside improvements in arterial stiffness markers. Evidence for cardiovascular endpoints is rated strong based on this human RCT, though larger multi-center trials are needed to confirm long-term outcomes. Preclinical data further support antioxidant and anti-inflammatory mechanisms, reinforcing the clinical findings.

Nutritional Profile

Capros is a standardized aqueous extract of Phyllanthus emblica (Indian gooseberry) fruit, primarily valued for its concentrated polyphenolic and bioactive compound profile rather than macronutrient content. Key bioactive compounds: Low-molecular-weight hydrolyzable tannins including emblicanin-A (~37% of polyphenolic fraction), emblicanin-B (~33%), punigluconin (~12%), and pedunculagin (~14%). Total polyphenol content: approximately 60-70% (w/w) as gallic acid equivalents, significantly higher than crude amla fruit (~2-3%). Contains gallic acid, ellagic acid, and their derivatives as primary phenolic acids. Rich in superoxide dismutase (SOD)-like activity compounds. Vitamin C content in the extract is relatively low compared to whole fruit (~0.5-1% w/w) due to aqueous extraction process favoring tannin concentration over ascorbic acid. Mineral content is minimal and not a primary contributor to bioactivity. Typical dosing in clinical trials: 250-500 mg twice daily (500-1000 mg/day). Bioavailability notes: The low-molecular-weight tannins in Capros demonstrate superior bioavailability compared to high-molecular-weight polyphenols found in other botanical extracts; emblicanins are water-soluble and relatively stable at gastric pH, allowing effective intestinal absorption. The hydrolyzable tannin matrix undergoes partial hydrolysis in the gut, releasing gallic acid and ellagic acid which are further metabolized by gut microbiota into urolithins, extending the bioactive half-life. The aqueous standardized extraction process (proprietary to Natreon Inc.) specifically enriches for these bioavailable low-molecular-weight polyphenols while excluding poorly absorbed high-molecular-weight proanthocyanidins. No significant protein, fat, or fiber content at effective supplemental doses.

Preparation & Dosage

Clinically studied doses include 500mg/day (250mg twice daily) and 1000mg/day (500mg twice daily) in capsule form, with the higher dose showing superior efficacy for cardiovascular benefits in 12-week trials. Studies used standardized aqueous extracts rich in polyphenols. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Coenzyme Q10, Omega-3 fatty acids, Magnesium, Vitamin D3, Hawthorn extract

Safety & Interactions

Capros is generally well tolerated at studied doses of 250–500 mg/day, with no serious adverse events reported in published clinical trials. Due to its mild antiplatelet and anticoagulant properties mediated through tannin-driven thromboxane A2 inhibition, caution is advised when combining Capros with blood-thinning medications such as warfarin, aspirin, or clopidogrel. Individuals with known hypersensitivity to Phyllanthus emblica or related Phyllanthaceae species should avoid use. Safety data during pregnancy and lactation are insufficient, so use is not recommended in these populations without physician guidance.